MIRA PHARMACEUTICALS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on December 19, 2024, by MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a Florida corporation. The filing reports a significant corporate event under Item 8.01 (Other Events) regarding the advancement of its lead drug candidate.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory milestone.
Material Changes and Events
- IND Submission: On December 19, 2024, the Company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ketamir-2.
- Drug Profile: Ketamir-2 is a novel oral ketamine analog designed to treat neuropathic pain.
- Preclinical Results: Studies indicated the potential for full pain reversal with no adverse safety findings.
Guidance, Outlook, and Risks
- Clinical Timeline: Management expects to initiate Phase I clinical trials in Q1 2025, followed by Phase IIa trials in late 2025.
- Forward-Looking Statements: The filing contains forward-looking statements regarding study benefits and timelines, which are subject to risks and uncertainties that could cause actual results to differ materially.
- Risk Reference: Detailed risks are referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
Investor Verification Checklist
- Confirm the FDA's acceptance of the IND application for Ketamir-2.
- Monitor the actual start date of Phase I clinical trials against the Q1 2025 target.
- Review the Form 10-K for the year ended December 31, 2023, for detailed risk factors and current financial liquidity status.
- Verify the Company's cash runway to support the anticipated clinical trial phases in 2025.